Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive ductal adenocarcinoma of the head, neck, and uncinate process of the pancreas~  * Mixed adenocarcinoma tumors allowed if the predominant invasive component of the tumor is adenocarcinoma~ * Stage I or II (clinical stage T1-3, N0-1, M0) disease~* Has undergone pancreaticoduodenectomy at the Johns Hopkins Hospital within the past 8-10 weeks~  * Completely resected (R0) or microscopic residual (R1) disease~* No diagnosis other than ductal adenocarcinoma, including any of the following:~  * Adenosquamous~ * Squamous cell~ * Colloid~ * Islet cell~ * Non-invasive intraductal papillary mucinous neoplasms~ * Serous or mucinous cystadenoma or cystadenocarcinoma~ * Carcinoid~ * Small or large cell carcinoma~ * Intraductal oncocytic papillary neoplasms~ * Osteoclast-like giant cell tumors~ * Acinar cell carcinoma~ * Pancreatoblastoma~ * Solid pseudopapillary tumors~ * Undifferentiated small cell carcinoma~ * Non-epithelial tumors (sarcoma, gastrointestinal stromal tumor, or lymphoma)~ * Adenocarcinoma of the ampulla~ * Adenocarcinoma of the distal bile duct~ * Adenocarcinoma of the duodenum~* No recurrent disease~* No metastatic disease, including peritoneal implants or liver and/or lung involvement~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count \>/= 1,500/mm\^3~* Platelet count \>/= 100,000/mm\^3~* Hemoglobin \>/= 10 g/dL~Hepatic~* Bilirubin \</= 2 mg/dL~* AST/ALT \</= 2 times upper limit of normal (ULN)~* Alkaline phosphatase \</= 5 times ULN~Renal~* Creatinine \</= 2 mg/dL~Pulmonary~* No asthma or chronic obstructive pulmonary disease requiring systemic corticosteroids~Immunologic~* HIV negative~* No active infection~* No prior or concurrent autoimmune disease requiring treatment with systemic immunosuppressants, including any of the following:~  * Inflammatory bowel disease~ * Systemic vasculitis~ * Scleroderma~ * Psoriasis~ * Multiple sclerosis~ * Hemolytic anemia or immune thrombocytopenia~ * Rheumatoid arthritis~ * Systemic lupus erythematosus~ * Sjogren's syndrome~ * Sarcoidosis~* Negative results to viral delayed-type hypersensitivity serology testing if autologous tumor cells are available~Other~* No postoperative complications (e.g., inability to take oral nutrition \>/= 1,500 calories/day, ongoing requirement for long-term biliary stenting, or persistence of wound infection)~* No other malignancy within the past 5 years except nonmelanoma skin cancer~* No uncontrolled medical conditions that would preclude study participation~* No other major active medical or psychosocial problem that could be exacerbated by study treatment~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 4 weeks after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 1 month since prior biologic therapy~* No other concurrent biologic therapy, immunotherapy, or gene therapy for pancreatic cancer~Chemotherapy~* More than 1 month since prior chemotherapy~* No other concurrent chemotherapy for pancreatic cancer~Endocrine therapy~* More than 28 days since prior systemic steroids~* No concurrent systemic corticosteroids~Radiotherapy~* More than 1 month since prior radiotherapy~* No other concurrent radiotherapy for pancreatic cancer~Surgery~* See Disease Characteristics~* Recovered from prior surgery~Other~* More than 1 month since prior participation in an investigational new drug trial~* No other concurrent investigational therapy for pancreatic cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GVAX pancreatic cancer vaccine (Type: EXPERIMENTAL): 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).